Open AccessSafety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial
Author(s) -
John S. Bradley,
Emmanuel Roilides,
Helen Broadhurst,
Karen Cheng,
LiMin Huang,
Veronica MasCasullo,
Paul Newell,
Gregory G. Stone,
Margaret Tawadrous,
Dalia Wajsbrot,
Katrina Yates,
Annie Gardner
Publication year - 2019
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000002395
Subject(s) - cefepime , medicine , ceftazidime/avibactam , ceftazidime , avibactam , adverse effect , surgery , anesthesia , genetics , bacteria , pseudomonas aeruginosa , biology
Ceftazidime-avibactam is effective and well tolerated in adults with complicated urinary tract infection (cUTI), but has not been evaluated in children with cUTI.